Impact of the Normalized Copy Number of <i>BCR-ABL</i>Transcript upon Diagnosis on Prognosis in CML Patients Treated with Imatinib-Mesylate

作     者：Christophe Martinaud Aurélie Mayet Sophie Bousquet Nathalie Beaufils Jean Gabert Sophie Raynaud Marie-Joelle Mozziconacci 

作者机构：不详 

出 版 物：《Open Journal of Blood Diseases》 (血液病期刊（英文）)

年 卷 期：2011年第1卷第2期

页      面：12-14页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Chronic Myeloid Leukemia RQ-PCR Normalized Copy Number BCR-ABL 

摘      要：Quantification of the BCR-ABL transcript is recommended to follow-up CML patients treated by imatinib mesylate (IM). Results are expressed as a normalized copy number (NCN) of BCR-ABL. We studied a cohort of 98 CML patients under IM as a first treatment and monitored by RQ-PCR after 12, 18 and 24 months according to the European LeukemiaNet recommendations. Our results support the hypothesis of an independent correlation between BCR-ABL NCN at diagnosis and major molecular response at 18 and 24 months in an inverse relationship. We also highlighted the possibility to use the NCN at diagnosis as a warning at diagnosis, and may be useful to identify patients who could benefit of a more rigorous follow-up.